Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells. - Wikidata - awgldk - TriplyDB

Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells.

Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells.

http://www.wikidata.org/entity/Q36831348

about

Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer.Role of 14-3-3σ in poor prognosis and in radiation and drug resistance of human pancreatic cancers.Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.Can drugs enhance hypofractionated radiotherapy? A novel method of modeling radiosensitization using in vitro data RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy.Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.Combination of carbon ion beam and gemcitabine causes irreparable DNA damage and death of radioresistant pancreatic cancer stem-like cells in vitro and in vivo.MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients.Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models.

P2860

Q28074614-9B417078-12F1-4CB3-855E-00B47F5EE988 Q33408075-A3D99DD8-7B5A-4B41-86E8-13685D9BAD83 Q33735346-E2565A26-FF9A-4A2E-92B0-4FD5FEA67E5C Q33926817-DC6DBB3D-DF17-4C16-8CF3-3C1C033526CA Q34134930-47F4E0C4-592E-4C2E-B1E4-F27B1DD1B326 Q34165809-A778E79A-E5AE-423A-8C94-972372589AC5 Q35023976-09016C9F-8DDF-4AB3-8428-A46D7D597675 Q35737519-B0C3B3B6-351B-40A8-AD78-7C98C9E4496E Q35742348-2931F789-2858-4845-AF97-7A702E850629 Q35839058-C6410FA3-5EE1-4992-B5AF-E9EF60B7FED0 Q37230970-565B96AB-7AA7-4284-8B93-AD61BA11EBDA Q37253577-2FE9206C-AA80-4B33-91EB-FDA101F2E56B Q37545395-960682C2-BC6C-4D6B-BF01-F7897B42817E

P2860

Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells.

http://www.wikidata.org/entity/Q36831348

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells.

@en

type

label

Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells.

@en

prefLabel

Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells.

@en

P1433

Q36831348-AC5D637D-2FB0-4DFA-AAA3-9B2BAE899AF1

P1476

Q36831348-DADF595D-5120-4C54-B1A1-939484BC1347

P2093

Q36831348-12AB321C-BF32-4941-9061-BBDDF0603785

Q36831348-43C69A7D-9C73-4393-A1B7-23826622B568

Q36831348-4D1E6370-5341-4088-9E0D-D92F4736FE56

Q36831348-60BDD6B5-5BB0-4314-972A-5A4B64E1A2D9

Q36831348-C1438E19-E587-4289-8555-62308AF41237

Q36831348-FCE81F6D-6543-4573-80F0-97D182F21F21

P2860

Q36831348-028B6155-3FF6-4E62-9F78-F290C5CFE3E4

Q36831348-2B34B6BB-E919-40D2-83FB-C31DB7E9E1AF

Q36831348-3445440B-A63D-4855-ACB0-DA37C6F688F4

Q36831348-41B659FA-BCBA-489D-944E-4E3E46CAC219

Q36831348-478BEA61-8526-4A5E-9ECF-A96B2B0CBEA9

Q36831348-4E1E833D-AF63-41AE-AB70-C25DCE453357

Q36831348-603B87DB-4E75-4A19-A7F0-1D82AB651F37

Q36831348-6CE91133-9215-4A51-B370-BA0A827C1A28

Q36831348-6EE32BEF-6681-4CE3-8AD0-D2A1640D6046

Q36831348-79918BB0-EC61-4E12-AA74-D55A5FEAFB58

P304

Q36831348-A7161EE4-41D7-4719-A8BD-3E906B0E0373

P31

Q36831348-9BE05B43-5985-4721-8923-A17D92420897

P356

Q36831348-42A02FF1-78A4-482E-9578-86DC70130674

P433

Q36831348-48398797-8F30-44B5-8C8C-3269816E4EAF

P478

Q36831348-F0F91FA9-4F38-47EA-9C6E-39DCFE34EFB0

P577

Q36831348-ACAD6449-3E8E-4BBC-B353-F098C67C494B

P5875

Q36831348-83D2D46D-4549-453E-9B92-AB71116F5DD9

P698

Q36831348-47E2C4E6-160B-49B5-B956-E35AA934DF0E

P932

Q36831348-3EA04779-6D0C-4E97-8B2E-625B465213F0

P356

P1433

Translational Oncology

P1476

Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells.

@en

P2093

Amichay Meirovitz

http://www.w3.org/2001/XMLSchema#string

Laura E Kollar

http://www.w3.org/2001/XMLSchema#string

Maria C Hassan

http://www.w3.org/2001/XMLSchema#string

Mary A Davis

http://www.w3.org/2001/XMLSchema#string

Meredith A Morgan

http://www.w3.org/2001/XMLSchema#string

Theodore S Lawrence

http://www.w3.org/2001/XMLSchema#string

P2860

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity.

Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma.

Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer.

Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer.

An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma.

Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer.

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation.

P304

36-43

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1593/TLO.07106

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2008-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5244435

http://www.w3.org/2001/XMLSchema#string

P698

18607506

http://www.w3.org/2001/XMLSchema#string

P932

2510762

http://www.w3.org/2001/XMLSchema#string